Cargando…

Role of Selexipag in Chronic Obstructive Pulmonary Disease (COPD) Patients With Out-of-Proportion Pulmonary Hypertension

Pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD) is associated with an increase in the risk of COPD exacerbation, increased hospitalization, and worse survival in this patient population. No specific treatment is available for PH in COPD. However, reported ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abuserewa, Sherif T, Selim, Ahmed, Youssef, Amr, Zolty, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376144/ https://www.ncbi.nlm.nih.gov/pubmed/34430131 http://dx.doi.org/10.7759/cureus.16520

Ejemplares similares

Evaluation of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
por: Aurangabadkar, Gaurang M, et al.
Publicado: (2022)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

The use of iloprost in the treatment of ‘out of proportion’ pulmonary hypertension in chronic obstructive pulmonary disease
por: Lasota, Bartosz, et al.
Publicado: (2013)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Assessment of Cardiac Dysfunction in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Cross-Sectional Study
por: Mohammed, Rehab A, et al.
Publicado: (2023)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Features of Kidney Function in Patients With Comorbidity of Arterial Hypertension and Chronic Obstructive Pulmonary Disease
por: Boiko, Olha, et al.
Publicado: (2022)

Obstructive Sleep Apnea and Pulmonary Hypertension: A Review of Literature
por: Shah, Farhan A, et al.
Publicado: (2021)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Multifactorial Pulmonary Hypertension in Systemic Sclerosis
por: Hussain, Habiba, et al.
Publicado: (2020)

The Coexistence of Chronic Obstructive Pulmonary Disease and Heart Failure
por: Khalid, Khizer, et al.
Publicado: (2021)

The Obesity Paradox in Chronic Heart Disease and Chronic Obstructive Pulmonary Disease
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

A Case of Chronic Pulmonary Embolism Resulting in Pulmonary Hypertension and Decompensated Right Heart Failure
por: Hosna, Asma U, et al.
Publicado: (2022)

Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension
por: Zolty, Ronald
Publicado: (2021)

Electrocardiographic Abnormalities in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
por: Kumar, Wikram, et al.
Publicado: (2021)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients
por: Youssef, David, et al.
Publicado: (2023)

Relationship Between Soluble ST2 Level and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Acute Pulmonary Embolism (PE) Patients
por: Kerkütlüoğlu, Murat, et al.
Publicado: (2023)

The Importance of Measuring Troponin in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review
por: Elmenawi, Khaled A, et al.
Publicado: (2021)

Platypnea-Orthodeoxia: An Effective Diagnostic Tool for Hepatopulmonary Syndrome With Chronic Obstructive Pulmonary Disease
por: Furuta, Yuzo, et al.
Publicado: (2023)

Infantile Scimitar Syndrome With Contralateral Pulmonary Vein Stenosis and Refractory Pulmonary Hypertension
por: Buysse, Janelle, et al.
Publicado: (2021)

Cardiac Papillary Fibroelastoma: Pulmonic Valve Involvement With Pulmonary Embolism and Pulmonary Hypertension
por: Jilani, Danish, et al.
Publicado: (2022)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Submassive Pulmonary Embolism Complicating Small Bowel Obstruction
por: Sagalov, Andrew, et al.
Publicado: (2021)

Treatment of Idiopathic Pulmonary Fibrosis
por: Abuserewa, Sherif T, et al.
Publicado: (2021)

Antiproliferative effect of selexipag active metabolite MRE‐269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension
por: Kuramoto, Kazuya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_br3si8ka0v4nfadc3j46hff15c